News
PCRX
20.55
-2.74%
-0.58
RBC Capital Sticks to Its Hold Rating for Pacira Pharmaceuticals (PCRX)
TipRanks · 18h ago
Rosen Law Firm Urges Pacira BioSciences, Inc. (NASDAQ: PCRX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Barchart · 1d ago
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky LLP about pending Class Action – PCRX
TipRanks · 1d ago
Pacira price target raised to $30 from $22 at Needham
TipRanks · 1d ago
Pacira (PCRX) Soars 11.1%: Is Further Upside Left in the Stock?
NASDAQ · 1d ago
6 Analysts Assess Pacira BioSciences: What You Need To Know
Benzinga · 1d ago
Pacira BioSciences Is Maintained at Buy by Needham
Dow Jones · 1d ago
Pacira BioSciences Price Target Raised to $30.00/Share From $22.00 by Needham
Dow Jones · 1d ago
Truist Financial Remains a Sell on Pacira Pharmaceuticals (PCRX)
TipRanks · 1d ago
PACIRA BIOSCIENCES INC <PCRX.O>: NEEDHAM RAISES TARGET PRICE TO $30 FROM $22
Reuters · 1d ago
PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales
Barchart · 1d ago
Pacira Pharmaceuticals: Strong Growth Prospects and Strategic Goals Drive Buy Rating
TipRanks · 1d ago
Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $30
Benzinga · 1d ago
Weekly Report: what happened at PCRX last week (0106-0110)?
Weekly Report · 1d ago
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
Benzinga · 4d ago
Pacira sees FY24 revenue $701M, consensus $695.18M
TipRanks · 4d ago
Pacira announces five-year objectives to accelerate transition
TipRanks · 4d ago
Pacira reports Q4 EXPAREL net product sales $147.7M vs. $143.9M last year
TipRanks · 4d ago
Pacira Reports Prelim. 2024 Revenue Of $710M vs $675.0M YoY; Co. Sets 2030 Goals Including More Than 3M Patients Treated Yearly
Benzinga · 4d ago
PACIRA BIOSCIENCES: SEES DOUBLE-DIGIT COMPOUNDED ANNUAL GROWTH RATE IN PRODUCT REVENUE BY 2030
Reuters · 4d ago
More
Webull provides a variety of real-time PCRX stock news. You can receive the latest news about Pacira Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About PCRX
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.